Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma

Haematologica

Volumn 92, Issue 2, 2007, Pages 269-270

  Oki, Yasuhiro ^b   Georgakis, Georgios V ^b   Migone, Thi Sau ^b   Kwak, Larry W ^b   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

BLyS; Hodgkin's lymphoma; Prognostic factor

Indexed keywords

MEMBRANE PROTEIN; PROTEIN B LYMPHOCYTE STIMULATOR; UNCLASSIFIED DRUG; B CELL ACTIVATING FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; PROGNOSIS; BLOOD; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; LETTER; MIDDLE AGED; PHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 33947517368     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10678     Document Type: Article

References (10)

1. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64.
2. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-88.
3. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79.
4. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003;78:106-13.
5. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002;100:2973-9.
6. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103:689-94.
7. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin's lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247-53.
8. Chiu A, Qiao X, He B, Hyjjek E, Lee J, Cesarman E. The TNF family members BAFF and APRIL play an important role in Hodgkin's lymphoma. Blood 2005;106:[abstract 22].
9. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.